Literature DB >> 2783437

Organ-specific autoimmune disease induced in mice by elimination of T cell subsets. V. Neonatal administration of cyclosporin A causes autoimmune disease.

S Sakaguchi1, N Sakaguchi.   

Abstract

Cyclosporin A (CsA), a potent immunosuppressive drug, caused organ-specific autoimmune disease, such as gastritis with anti-parietal cell autoantibodies or oophoritis with anti-oocyte autoantibodies, in BALB/c mice when the drug was administered daily for 1 wk to newborns. Administration to adult mice did not. CsA abrogated the production of L3T4+ T cells and Lyt-2+ T cells in the thymus. Consequently, these T cells were substantially depleted from the peripheral lymphoid organs, especially when the drug was administered from the day of birth. Autoimmune disease was prevented when CsA-treated newborn mice were inoculated with splenic T cells from normal syngeneic mice. However, removal of the thymus immediately after neonatal CsA treatment produced autoimmune disease with a higher incidence and in a wider spectrum of organs, i.e., thyroiditis, sialoadenitis of the salivary gland, gastritis, insulitis of the endocrine pancreas, adrenalitis, oophoritis, or orchitis. Each autoimmune disease was accompanied by the development of circulating autoantibodies specific for the corresponding organ Ag. Immunopathology of these autoimmune diseases was quite similar to that of human organ-specific autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2783437

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  41 in total

1.  Chronic remitting experimental allergic encephalomyelitis in Lewis rats as a model of multiple sclerosis.

Authors:  E Zapryanova; D Deleva; M Bakalska; N Filchev
Journal:  Neurosci Behav Physiol       Date:  1999 Jan-Feb

2.  Organ-specific and systemic autoimmune diseases originate from defects in hematopoietic stem cells.

Authors:  S Ikehara; M Kawamura; F Takao; M Inaba; R Yasumizu; S Than; H Hisha; K Sugiura; Y Koide; T O Yoshida
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

Review 3.  CD4+ regulatory cells as a potential immunotherapy.

Authors:  Zoltán Fehérvari; Shimon Sakaguchi
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2005-09-29       Impact factor: 6.237

4.  Patterns of MHC antigenic modulation in cyclosporine-induced autoimmunity. Implications for pathogenesis.

Authors:  N A Parfrey; G J Prud'homme
Journal:  Am J Pathol       Date:  1990-02       Impact factor: 4.307

5.  MiR-548a-3p Promotes Keratinocyte Proliferation Targeting PPP3R1 after Being Induced by IL-22.

Authors:  Xintong Zhao; Ronghua Li; Meng Qiao; Jianjun Yan; Qing Sun
Journal:  Inflammation       Date:  2018-03       Impact factor: 4.092

6.  Spontaneous development of organ-specific autoimmune lesions in aged C57BL/6 mice.

Authors:  Y Hayashi; M Utsuyama; C Kurashima; K Hirokawa
Journal:  Clin Exp Immunol       Date:  1989-10       Impact factor: 4.330

7.  Neonatal injections of cyclosporin enhance autoimmune diabetes in non-obese diabetic mice.

Authors:  P Saï; O Senecat; L Martignat; E Gouin
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

8.  Lung Injury Combined with Loss of Regulatory T Cells Leads to De Novo Lung-Restricted Autoimmunity.

Authors:  Stephen Chiu; Ramiro Fernandez; Vijay Subramanian; Haiying Sun; Malcolm M DeCamp; Daniel Kreisel; Harris Perlman; G R Scott Budinger; Thalachallour Mohanakumar; Ankit Bharat
Journal:  J Immunol       Date:  2016-05-18       Impact factor: 5.422

Review 9.  Autoimmune polyglandular syndrome Type 2: the tip of an iceberg?

Authors:  C Betterle; F Lazzarotto; F Presotto
Journal:  Clin Exp Immunol       Date:  2004-08       Impact factor: 4.330

10.  A novel and effective approach of developing aggressive experimental autoimmune gastritis in neonatal thymectomized BALB/c mouse by polyinosinic:polycytidylic acid.

Authors:  Y Kobayashi; H Murakami; S M F Akbar; H Matsui; M Onji
Journal:  Clin Exp Immunol       Date:  2004-06       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.